Therapeutics/Diagnostics News

Autonomous AI exhibited “noninferior accuracy” for optical diagnosis of diminutive colorectal polyps vs. AI-assisted endoscopists, yet surpassed endoscopist accuracy in later pathology-based surveillance intervals, according to researchers.

Remaining current on screening for hepatocellular carcinoma correlated with a “survival benefit” in older adults with hepatitis C virus-related cirrhosis who achieved viral cure but later developed HCC, according to researchers.

Multimodal intestinal ultrasound performed at 24 weeks can provide “useful information” for predicting endoscopic response at 1 year in patients with active Crohn’s disease initiating treatment with Stelara, according to researchers.

In a dose-dependent manner, fazirsiran reduced serum and liver concentrations of Z-AAT and also improved histological measures in patients with homozygous ZZ alpha-1 antitrypsin deficiency-associated liver disease, according to data.

Tenofovir alafenamide was safe and maintained virological response in patients with chronic hepatitis B virus infection and renal or hepatic impairment who switched from tenofovir disoproxil fumarate or other antivirals, according to data.

The FDA has expanded approval for Phathom Pharmaceuticals’ Voquezna tablets 10 mg to alleviate heartburn related in non-erosive gastroesophageal reflux disease, according to a company press release.

AI has already made its mark in gastroenterology as a tool for detecting gastrointestinal lesions, adenomas and inflammatory bowel disease. However, its next phase of evolution might seem the most unlikely: Aiding colonoscopy preparation.

The FDA has granted orphan drug designation to PharmassêtX’s PSX-514, a drug derived from an active component of green tea, for the treatment of pouchitis, according to a company press release.

In a Healio exclusive, Andres J. Acosta, MD, PhD, highlights data demonstrating that the MyPhenome test may serve as a biomarker to determine whether a patient with obesity will be a “good responder” to semaglutide.

Tofacitinib “should be considered as a treatment option” for patients with refractory celiac disease type 2 who previously failed treatment with therapies such as budesonide, according to data in Clinical Gastroenterology and Hepatology.